ArticleTranslational cancer research2026
Gene expression profile, and role of baicalein in the inhibition of thyroid cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anaplastic thyroid cancer (ATC) is the highly undifferentiated form of thyroid cancer, and its incidence is still high all around the globe. The current treatment for ATC includes surgery, chemotherapy, and radioactive iodine therapy. These treatment options are not reliable due to high cost, drug resistance, and toxicity issues. Baicalein (BA) is a natural flavonoid isolated from Methods: Differential gene expression and pathway enrichment were assessed using RNA sequencing and gene set enrichment analysis (GSEA). Mitochondrial fluorescence and mitophagy markers (PINK1, PRKN, ATG5, MFN1) were evaluated by quantitative polymerase chain reaction (qPCR) and fluorescence microscopy. CLU expression and its correlation with cancer progression were analyzed using The Cancer Genome Atlas (TCGA) data. Results: BA treatment altered gene expression and pathway activity, impacting processes including cell proliferation, mitophagy, and epithelial-mesenchymal transition. It reduced the mitochondrial fluorescence intensity and mitophagy marker levels, consistent with an inhibition of mitophagy. BA also modulated thyroid cancer markers, indicating the induced dedifferentiation. TCGA analysis confirmed the CLU upregulation in thyroid cancer, linking it to disease progression and survival. BA inhibits ATC cell growth, an effect associated with the alteration of CLU-linked mitophagy and key signaling pathways. Conclusions: These findings highlight that CLU as a potential therapeutic target and suggested BA as a promising strategy for thyroid cancer intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.